Survival benefit in EGFR-wild and ALK negative NSCLC patients who participate in clinical trials compared to standard-of-care: Propensity-matched analysis

Over the past two decades, remarkable progress has been made in therapeutic applications for non-small-cell lung cancer (NSCLC), with fundamental knowledge of tumor biology and drug development. Notably, spectacular advances in the management of NSCLC have been accomplished in clinical trials.
Source: Lung Cancer - Category: Cancer & Oncology Authors: Tags: Research Paper Source Type: research